black lucky cat movie
Matt Gaetz will still be in Trump’s admin despite AG drop out – real ‘million-dollar question’ is on Musk, expert saysPASADENA, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) — via IBN – VenHub, a disruptive AI and robotics company (“VenHub” or the “Company”), and (NASDAQ: TGAA) (“TGAA”), a NASDAQ-listed special purpose acquisition company, today announced they have entered into a definitive business combination agreement, dated as of December 2, 2024 (the “Business Combination Agreement”). The proposed business combination (the “Proposed Business Combination”) is expected to be completed (the “Closing”) in the second quarter of 2025, subject to customary closing conditions, including regulatory and shareholder approvals. The combined company will operate as VenHub Global Holdings, Inc. following the Closing and is expected to list on Nasdaq under the ticker symbol “VHUB”. As one of the leading providers of a 24/7 autonomous smart store, VenHub has introduced and developed a solution with the potential to transform how consumers interact with technology in retail environments. Powered by proprietary software and unique robotics arms technology, VenHub’s product offering can provide a seamless customer experience. Manufactured by a leader in the global robotics industry, the innovative robotic arms technology can differentiate VenHub from traditional retail solutions and well-positions the Company in the automated retail space. Additionally, VenHub’s cutting edge vision system adds precision and reliability to its product offering, and the efficiency and security of the Smart Stores are enabled by VenHub’s intellectual property portfolio. Founded in 2023, VenHub is addressing challenges facing traditional retail stores, including inefficient inventory management, limited hours, high labor costs, and security concerns. The Smart Stores are designed to utilize data-driven inventory management, a self-service delivery system, and advanced security protection, all of which reduce labor costs and collectively enhance sales and growth potential. Through these potential competitive advantages, VenHub has secured over 1,000 customer pre-orders across 48 states, with potential revenue of more than $300 million in pre-order value. This pre-order book demonstrates market confidence in VenHub’s smart store technology. VenHub’s growth strategy focuses on geographic and store format expansion to meet the growing demand for autonomous retail solutions, as well as product diversification to enhance VenHub’s market presence and operational efficiency. The Company’s CapEx-light business model has the potential to create value for stakeholders, and its diversified business model with potential for recurring revenue can allow VenHub to achieve its expansion plan. : “This is day one for VenHub on a larger stage,” Shahan Ohanessian, CEO of VenHub, remarked. “We’re at the starting line of what I believe will be a remarkable journey, turning our vision into reality and expanding our reach on a global scale. We’re not just joining the market; we’re aiming to pioneer a new frontier in smart retail that enhances how businesses and consumers connect.” : “We are excited to partner with Shahan and the VenHub team. VenHub’s efficient, capital-light business model, combined with strong near-term projected positive cash flow generation, positions the Company for sustainable growth. This approach enables strategic expansion into multiple geographic markets while leveraging internally generated cash flow and maintaining disciplined resource allocation.” The Proposed Business Combination implies a pro forma enterprise value of $715 million, which assumes an estimated equity value of $650 million, $26 million in new cash to the balance sheet (assuming 100% redemptions by TGAA public shareholders), and $0.6 million in existing cash. The Proposed Business Combination is expected to provide net cash to VenHub of up to $14 million to support VenHub’s continued geographic expansion and product diversification. Cash proceeds raised will consist of TGAA’s approximately $20.4 million cash in trust, net of redemptions. The cash in the TGAA trust account is anticipated to support the Company’s growth capital needs, including VenHub’s production, marketing and sales efforts. It is intended that 100% of existing VenHub stockholders will roll over their equity and, assuming no redemptions and full rollover, own approximately 89% of the pro forma equity of the combined company in connection with the transaction. The Proposed Business Combination has been approved by the boards of directors of both VenHub and TGAA and is expected to close in the second quarter of 2025, subject to shareholder approvals and other customary closing conditions. For a summary of the material terms of the Proposed Business Combination, as well as a supplemental investor presentation, please see the Current Report on Form 8-K filed today by TGAA with the U.S. Securities and Exchange Commission (the “SEC”). Additional information about the Proposed Business Combination will be described in TGAA’s proxy statement relating to the Proposed Business Combination, which it will file with the SEC. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, is serving as the exclusive financial advisor, capital markets advisor and placement agent to VenHub. Smith Eilers PLLC is serving as legal counsel to VenHub. Orrick, Herrington & Sutcliffe LLP is serving as legal counsel to TGAA. Travers Thorp Alberga is serving as legal counsel to TGAA with respect to Cayman Islands law. VenHub Global, Inc., f/k/a Autonomous Solutions, Inc., a Delaware corporation, is reshaping the retail industry with its groundbreaking autonomous and robotic-operated Smart Stores. Leveraging advanced AI and smart inventory management systems, VenHub offers a seamless shopping experience that operates 24/7. This approach not only increases revenue but also significantly reduces operational costs compared to traditional retail setups. VenHub’s modular design allows for quick installation and easy customization to meet a wide range of consumer needs. The company operates across three main retail formats: fixed Smart Stores for permanent locations, mobile Smart Stores for flexibility and broader accessibility, and innovative solutions that upgrade existing retail spaces and shopping centers into advanced Smart Shopping environments. With its forward-thinking strategy, VenHub is poised to transform the retail landscape, providing an efficient and accessible shopping experience that anticipates the future of commerce. TGAA Acquisition I Corp. is a blank check company incorporated as a Cayman Island exempted company and formed for the purpose of effecting a merger, share, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. TGAA’s units, Class A ordinary shares and warrants trade on the Nasdaq under the ticker symbols “TGAAU,” “TGAA,” and “TGAAW” respectively. This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. TGAA’s and VenHub’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, TGAA’s and VenHub’s expectations with respect to future performance and anticipated financial impacts of the Proposed Business Combination, the satisfaction of the closing conditions to the Proposed Business Combination and the timing of the completion of the Proposed Business Combination. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside TGAA’s and VenHub’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement, (2) the outcome of any legal proceedings that may be instituted against TGAA and VenHub following the announcement of the Business Combination Agreement and the transactions contemplated therein; (3) the inability to complete the Proposed Business Combination, including due to failure to obtain approval of the shareholders of TGAA or other conditions to closing in the Business Combination Agreement; (4) the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement or could otherwise cause the Proposed Business Combination to fail to close; (5) the amount of redemption requests made by TGAA’s shareholders; (6) the inability to obtain or maintain the listing of the post-business combination company’s common stock on the Nasdaq Stock Market LLC following the Proposed Business Combination; (7) the risk that the Proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Proposed Business Combination; (8) the ability to recognize the anticipated benefits of the Proposed Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the Proposed Business Combination; (10) changes in applicable laws or regulations; (11) the possibility that VenHub or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties indicated from time to time in the proxy statement relating to the Proposed Business Combination, including those under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” which will be set forth in a Registration Statement on Form S-4 (the “Registration Statement”) to be filed by TGAA and the Company and in TGAA’s other filings with the SEC. Some of these risks and uncertainties may be amplified by future events and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. TGAA cautions that the foregoing list of factors is not exclusive. TGAA cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date they are made. TGAA does not undertake or accept any obligation or undertaking to update or revise any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based This press release relates to a proposed transaction between the Company and TGAA. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. TGAA and the Company intend to file a registration statement on Form S-4 that will include a proxy statement/prospectus of TGAA. The proxy statement/prospectus will be sent to all TGAA shareholders. TGAA also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of TGAA are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the registration statement and all other relevant documents filed or that will be filed with the SEC by TGAA through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by TGAA may be obtained free of charge from TGAA’s website at https://tgacquisition1.com/ or by written request to TGAA at: Target Global Acquisition I Corp., PO Box 10176, Governor’s Square 23, Lime Tree Bay Avenue, Grand Cayman KY1-1102, Cayman Islands. TGAA and the Company and their respective directors and officers may be deemed to be participants in the solicitation of proxies from TGAA’s shareholders in connection with the proposed transaction. Information about TGAA’s directors and executive officers and their ownership of TGAA’s securities is set forth in TGAA’s filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph. This press release is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of TGAA, VenHub or any of their respective affiliates. No such offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. The contents of this press release have not been reviewed by any regulatory authority in any jurisdiction. IR@VenHub.com 888-585-4999 : IBN Los Angeles, California 310.299.1717 Office Grand View Research, “GVR Report cover Convenience Stores Market Size, Share & Trends Analysis Report By Type (Cigarettes & Tobacco, Foodservice, Packaged Beverages, Center Store, Low Alcoholic Beverages), By Region, And Segment Forecasts, 2022 – 2028”, May 2022 Based on management estimates. As of September 30, 2024.Dec 1, 2024; Orchard Park, New York, USA; San Francisco 49ers running back Christian McCaffrey (23) is tackled by Buffalo Bills safety Taylor Rapp (9) and safety Damar Hamlin (3) in the second quarter at Highmark Stadium. Mark Konezny-Imagn Images/File Photo Dec 1, 2024; Orchard Park, New York, USA; San Francisco 49ers running back Jordan Mason (24) avoids a tackle by Buffalo Bills cornerback Rasul Douglas (31) in the third quarter at Highmark Stadium. Mark Konezny-Imagn Images/File Photo San Francisco 49ers running back Christian McCaffrey and top backup Jordan Mason are being placed on injured reserve. McCaffrey left the snowy field in Buffalo on Sunday night after a 5-yard gain that was preceded by him heading to the sideline in apparent pain at the end of an 18-yard run. McCaffrey was diagnosed with a posterior cruciate ligament injury in his right knee and did not play in the second half. The 49ers also lost Jordan Mason, who emerged in a starting role with McCaffrey out the first two months of the season, to an ankle injury. Head coach Kyle Shanahan said Monday that Mason has a high-ankle sprain, which typically requires a recovery window of 4-6 weeks. Those moves push rookie Isaac Guerendo into the RB1 spot. He scored the team's only touchdown at Buffalo. The IR slots in San Francisco are manned by multiple starters, including wide receiver Brandon Aiyuk, linebacker Dre Greenlaw, defensive tackle Javon Hargrave and safety Talanoa Hufanga. Mason had a team-leading 789 rushing yards and scored three touchdowns. Being placed on IR means he's not eligible to play until the regular-season finale at Arizona. McCaffrey had 53 yards on seven carries on Sunday night and caught two passes for 14 yards before exiting. He was playing in just his fourth game of the season after missing the first eight because of Achilles tendinitis. McCaffrey was the NFL Offensive Player of the Year last season, when he led the league with 2,023 yards from scrimmage: a league-leading 1,459 rushing yards and 14 touchdowns plus 67 catches for 564 yards and seven scores. McCaffrey hasn't scored a touchdown in his four appearances this season. He has rushed for 202 yards on 50 carries and caught 15 passes for 146 yards. "It was frustrating," Shanahan said after the game. "He had a great week of practice and I could feel his urgency and stuff and thought he came out great, looking really good, and it looked like he just got his shoestring there. ... I hurt for him, and tough for our team not having him." The 49ers (5-7) played without defensive end Nick Bosa (oblique) and left tackle Trent Williams (ankle) in the 35-10 loss. San Francisco has lost three in a row heading into next Sunday's game against the Chicago Bears (4-8) in Santa Clara, Calif. San Francisco resides two games behind the NFC West-leading Seattle Seahawks (7-5) with five games remaining on the schedule. Seattle and San Francisco split their season series. --Field Level Media REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you. Read 3 articles and stand to win rewards Spin the wheel nowTest Drive: 2025 Genesis GV80 a major focus for luxury automaker
None
Marcus Johnson and Bowling Green take down New Mexico State 61-60
Stock market today: Wall Street gets back to climbing, sending Nasdaq to a recordChâtillon, France, December 11 th , 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025 Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-old Company to host investor webcast today at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 – 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old. DBV and FDA have agreed on the key design elements for a post-marketing confirmatory study. “DBV is pleased to have received, what we believe to be, a clear and reasonable pathway towards an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old. This comes on the heels of our October 22 nd press release announcing details in support of our separate Viaskin Peanut programs in 4 – 7 year-olds and in 1 – 7 year-olds in Europe,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “We believe we have decreased the regulatory pathway risk of our programs. DBV can now fully focus on executing the remaining studies that will support two distinct BLAs across age groups and an MAA in Europe. We are grateful to the Agency for its attentive collaboration as we continue to work towards introducing this novel therapy to caregivers and patients as expeditiously as possible.” Accelerated Approval Pathway The FDA recently issued written communication confirming an Accelerated Approval pathway for the Viaskin Peanut patch in toddlers 1 – 3-years-old. As a reminder, current FDA guidance for Accelerated Approval includes three qualifying criteria: That the product candidate treats a serious condition That the product candidate generally provides a meaningful advantage over available therapies That the product candidate demonstrates an effect or an intermediate clinical endpoint that is reasonably likely to predict clinical benefit As DBV previously announced , FDA confirmed via written communication that the Viaskin Peanut patch already met criteria one and two. FDA and DBV have been engaged in ongoing dialogue throughout Q4 of this year regarding the intermediate clinical endpoint necessary to meet the third criterion. In the recent written communication, the FDA confirmed the efficacy data from the Company’s Phase 3 EPITOPE study can serve as an intermediate clinical endpoint. The FDA has agreed that the endpoint is reasonably likely to predict clinical benefit and will therefore fulfill the requirement for Accelerated Approval. In preparation for commercialization, DBV made slight modifications to the Viaskin Peanut patch used in EPITOPE to increase the simplicity of application for the caregiver and provide product identification on each patch. No changes, including patch shape or size, were made to the device components that are in contact with the patient’s skin. Further, to increase the volume of patch production for future commercialization, changes needed to be made to the manufacturing process and location. Although the intended commercial Viaskin Peanut patch is currently being used (N=304) in the ongoing 3-year Open Label Extension to EPITOPE, the collective changes to the commercial Viaskin Peanut patch were viewed by the FDA as constituting a different product relative to the clinical patch used in the EPITOPE study. The Company intends to use the commercial Viaskin Peanut patch in both the COMFORT Toddlers study and the post-marketing confirmatory study. Post-Marketing Confirmatory Study In the recent written communication, FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1 – 3-years-old. DBV and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch and will need to be initiated at the time that the BLA is submitted. To date, the commercial patch has been used in 304 subjects with over 234,695 patient-days of therapy in the placebo crossover and the EPITOPE Open Label Extension, with no clinically relevant differences in efficacy or safety vs. the clinical patch used in the EPITOPE Phase 3 trial. The confirmatory study will include a double-blind, placebo-controlled food challenge (DBPCFC) and will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE Phase 3 efficacy study. Adhesion data for the post-marketing confirmatory study will be collected in a similar manner relative to the COMFORT Toddlers study. The Company expects these data will further support the importance of average daily wear time in the use of the Viaskin Peanut patch as it relates to efficacy and labeling. “When it comes to food allergy management, what works for one family, might not work for another. That is why having varied treatment options available is so incredibly important to our community,” said Sung Poblete, PhD, RN, CEO of FARE (Food Allergy Research & Education). “I’m pleased to learn that DBV’s constructive dialogue with the FDA has resulted in this Accelerated Approval guidance outlining remaining developmental steps for the Viaskin Peanut patch in toddlers with a peanut allergy. At FARE, we look forward to the possibility that one day, if approved, caregivers and families will have this exciting new treatment as an option to consider.” COMFORT Toddlers Supplemental Safety Study COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) study designed to generate additional safety (primary endpoint) and adhesion data of the Viaskin Peanut patch in peanut allergic toddlers 1 – 3-years old. DBV is pleased to announce that Dr. Julie Wang, MD, Professor of Pediatrics, Jaffe Food Allergy Institute, the Icahn school of Medicine at Mount Sinai, will act as the Global Principal Investigator for the COMFORT Toddlers study. “I am thrilled to assume the role of Global Principal Investigator of the COMFORT Toddlers study,” stated Dr. Julie Wang, Professor of Pediatrics, Jaffe Food Allergy Institute, Icahn school of Medicine at Mount Sinai in New York. “Viaskin Peanut, if approved, would offer a much-needed alternative treatment option for patients and caregivers. I look forward to working with the DBV team to advance this important clinical trial.” The Company anticipates that COMFORT Toddlers will enroll approximately 480 subjects randomized 3:1 (active: placebo) at approximately 80 – 90 study centers across the U.S., Canada, Australia, and Europe. COMFORT Toddlers will be a six-month study followed by an optional 18-month open-label treatment phase, to provide 24 or 18 months of treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively. Thus, the COMFORT Toddlers study will increase the total subjects exposed to the Viaskin Peanut patch for at least six-months in a controlled study to 600, as required by FDA. In total, there will be approximately 240 subjects with the clinical patch in EPITOPE and 360 with the commercial patch in COMFORT Toddlers. As previously disclosed , DBV and FDA have aligned on a patch wear time collection methodology, analysis and study objective hierarchy in the COMFORT Toddlers study. The agreed-upon adhesion data collection methodology provides a practical approach for subjects, families, and investigators. The methodology is intended to generate sufficient data to support a BLA submission under the Accelerated Approval pathway (i.e., collecting patch adhesion data with a focus on daily wear time at relevant time points). We believe there are three positive outcomes coming out of the productive discussions with FDA: FDA agreed that adhesion would not be a co-objective of a safety study and would be an exploratory endpoint. Next, adhesion should be assessed in the overall totality of benefit to risk (i.e., in the context of efficacy and safety). The third success is that we have aligned on what DBV believes is a very feasible approach to collecting adhesion data. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. Biologic License Application Submission in 1 – 3 Year-Olds There will be two Phase 3 studies in 1 – 3-year-olds using the Viaskin Peanut patch. The data generated from the studies will be used to inform a BLA submission: Twelve months of DBPC efficacy and safety data from the previously completed Phase 3 EPITOPE study (published in the New England Journal of Medicine i n May 2023), and 36 months of open-label extension data. Six months of DBPC data generated in COMFORT Toddlers supplemental safety study. DBV anticipates that the BLA for the Viaskin Peanut patch in toddlers 1 – 3 years-old under the Accelerated Approval program will be submitted in 2H 2026. Investor Conference Call and Webcast DBV management will host an investor conference call and webcast today, Wednesday, December 11 th , at 5:00pm EST, to discuss these regulatory updates. This call is accessible via the below teleconferencing numbers and requesting the DBV Technologies call. United States: +1-877-346-6112 International: +1-848-280-6350 A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/ . A replay of the presentation will also be available on DBV’s website after the event. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary Viaskin® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPITTM), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn . Forward Looking Statements This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin® Peanut patch and EPITTM, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations regarding initiation of the confirmatory study, plans and expectations with respect to COMFORT Toddlers and COMFORT Children, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, DBV’s expectations with respect to the Accelerated Approval pathway and any other actionable regulatory pathway, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies. Investor Contact Katie Matthews DBV Technologies katie.matthews@dbv-technologies.com Media Contact Angela Marcucci DBV Technologies angela.marcucci@dbv-technologies.com Attachment PDF Version
EIB and Naturgy Seal €1bn Deal to Boost Spain’s Renewable Capacity by 2.3 GWFrom Jelly Roll to TWICE, top acts hit 'Amazon Music Live' to spotlight their upcoming projects
Russell Rises to the Pole in Qatar GPPurdue vs. Indiana FREE LIVE STREAM (11/30/24): Watch college football, Week 14 online | Time, TV, channel
It’s one thing for a president to pardon his son. It’s another to do it like this. President Joe Biden’s pardon of his son , Hunter Biden, on Monday (AEDT) is exceptional not just because of the pardon’s recipient – the closest family member to receive a pardon in history – but also for its sheer breadth, according to experts on presidential pardons. President Joe Biden accompanied by his son Hunter Biden in Nantucket over the Thanksgiving holiday. Credit: AP Biden didn’t just pardon his son for his convictions on tax and gun charges , but for any “offences against the United States which he has committed or may have committed or taken part in during the period from January 1, 2014, through December 1, 2024”. That’s a nearly 11-year period during which any federal crime Hunter Biden might have committed – and there are none we are aware of beyond what has already been adjudicated – can’t be prosecuted. It notably covers when he was appointed to the board of the Ukrainian energy company Burisma in 2014 all the way through to Sunday, well after the crimes for which he was prosecuted. Hunter Biden hasn’t been charged for his activities regarding Burisma or anything beyond his convictions, and nothing in the public record suggests criminal charges could be around the bend. Congressional Republicans have probed the Burisma matter and Hunter Biden extensively and could seemingly have uncovered chargeable crimes if they existed, but haven’t done so. Hunter Biden after pleading guilty to federal tax charges in September. Credit: AP Even still, the scope of the pardon is remarkable. Experts say there is little to no precedent for a pardon covering such a wide range of activity over such a long period, with the closest being Gerald Ford’s 1974 pardon of Richard Nixon after Nixon resigned post-Watergate. Hunter Biden’s pardon “isn’t tied to any special counsel investigation or charging document,” Sam Morison, who spent 13 years working for the Justice Department’s Office of the Pardon Attorney, said via email. “The only pardon grant that comes close is Ford’s pardon of Nixon for any crimes he may have committed from 1969 to 1974, which on its face would have included crimes (if any) unrelated to Watergate.” Experts pointed to several broad, preemptive and blanket pardons that bear similarities to the one covering Hunter Biden. But they also feature some key differences. The language of the Nixon pardon cited crimes he “has committed or may have committed” between January 20, 1969, and August 9, 1974 – language similar to Hunter Biden’s pardon. Pardoned: Former US president Richard Nixon became infamous for the Watergate scandal. Credit: AP As noted, that is not Watergate-specific, and the dates cover Nixon’s entire presidency. But it’s a period roughly half as long as that covered under Hunter Biden’s pardon. There’s also the fact that some of Nixon’s actions might already have been exempt from prosecution by virtue of his role as president – something Hunter Biden doesn’t benefit from. In 1976 Jimmy Carter pardoned most of those who dodged the Vietnam War draft between August 4, 1964, and March 28, 1973. That covered a large group of people, but the pardon was only for violating the Military Selective Service Act and related regulations. Other presidents have also issued blanket amnesties for large groups of people tied to specific events or specific crimes. Benjamin Harrison did so in 1893 for Mormon polygamists, noting that they had “abstained from such unlawful cohabitation” by 1890. But that was, likewise, for a specific crime. US President Andrew Johnson pardoned 13,000 former Confederate soldiers. Credit: LOC Andrew Johnson issued individual pardons for 13,000 Confederate soldiers after the Civil War, granting them clemency for “all offences by him committed, arising from participation, direct or implied” in the rebellion. “These individual pardons were issued by Johnson throughout his term, and particularly during its first two years,” Frank O. Bowman III, a pardon expert at the University of Missouri School of Law, said in an email. “Hence, they reached back some 6–8 years.” George Washington did so in 1794 for participants of the Whiskey Rebellion, a tax revolt in Pennsylvania . The pardoned conduct was broad – the pardon was for those who had “directly or indirectly engaged in the wicked and unhappy tumults and disturbances lately” and encompassed residents of several counties – but it was at least tied to one event. A couple of other more recent examples that involve pardoning figures for crimes committed in high-profile scandals bear some similarities to the Hunter Biden pardon. Michael Flynn was pardoned by Donald Trump at the end of his first presidency. Credit: AP George H.W. Bush in 1992 pardoned six figures in the Iran-contra affair, including former defence secretary Caspar Weinberger, “for all offences charged or prosecuted by Independent Counsel Lawrence E. Walsh or other member of his office, or committed by these individuals and within the jurisdiction of that office”. And now-President-elect Donald Trump in 2020 pardoned former national security adviser Michael Flynn for “any and all possible offences” arising from facts or circumstances that were “in any matter related” to special counsel Robert Mueller’s Russia investigation. Broad clemency The latter went even further than the former, by pardoning Flynn for conduct even just somehow related to the special counsel’s investigation. At the time, some experts regarded it as the broadest act of clemency since Nixon’s pardon. Loading “Flynn’s pardon was broad, to be sure, but not nearly as broad as Hunter’s,” Morison said. There is some question about whether such a broad pardon for unspecified crimes is constitutional, an issue that arose when reports indicated Trump might preemptively pardon family members at the tail end of his first term. The Nixon pardon was not tested in court. But the Supreme Court said amid Johnson’s post-Civil War pardons that a president’s pardon power “extends to every offence known to the law, and may be exercised at any time after its commission, either before legal proceedings are taken or during their pendency or after conviction and judgment.” There is some subjectivity in comparing these pardons. Hunter Biden’s known actions come up well shy of the magnitude of participating in a rebellion against the United States or some of the high-profile scandals mentioned above, for example. And it’s worth emphasising how extraordinarily political many of Trump’s pardons were – granting clemency to numerous political allies and several people wrapped up in investigations involving Trump, including Flynn. Trump surely stretched the bounds of presidential pardon power. But there’s no question that Biden’s exercise of his pardon power also stretched those bounds - and on behalf of his son, no less. “The Nixon pardon is the only precedent in modern times for such a broad pardon, which purports to insulate Hunter Biden from prosecution for crimes that have not even been charged,” said Margaret Love, who served as US pardon attorney under George H.W. Bush and Bill Clinton. “Some of the Trump pardons were also disruptive of ongoing prosecutions,” Love said, adding that they were at least “directed to specific charged conduct”. Washington Post Save Log in , register or subscribe to save articles for later. US politics USA Joe Biden Analysis Trump's America US election Most Viewed in World Loading
Winless in rivalry, Dan Lanning, No. 1 Oregon determined to tame HuskiesMatt Gaetz will still be in Trump’s admin despite AG drop out – real ‘million-dollar question’ is on Musk, expert saysHarris puts up 24, Southern Miss defeats Milwaukee 66-65
None
After Black Friday and Cyber Monday, GivingTuesday celebrates giving and is critical for charities experiencing heightened demand for essential services TORONTO, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Spokespersons from CanadaHelps , co-founders of GivingTuesday Canada and Canada's largest online donation and fundraising platform, are available for media interviews to discuss GivingTuesday, which takes place this year on December 3rd. As many Canadians continue to struggle under financial pressure and are turning to charities to meet essential needs, CanadaHelps is highlighting how communities can unite this giving season by engaging in generosity. As the world's largest generosity movement, GivingTuesday celebrates and encourages all forms of giving, including donating, volunteering, performing acts of kindness, and more. More than $13.6 million was donated within 24 hours via CanadaHelps.org to support registered charities on GivingTuesday in 2023. This year, the organization is aiming to surpass last year's total. The holiday season is a critical fundraising time for charities with approximately 40% of annual donations being made in the final two months of the year on CanadaHelps.org. The generosity shown on GivingTuesday and throughout the rest of the year sustains the vital work of charities year-round. Spokespersons from CanadaHelps can discuss the following topics leading up to and on GivingTuesday: Demand For Charitable Services Generosity is especially critical given the record-breaking use of food banks reported across the country as Canadians struggle under financial pressures and turn to charities for daily essentials including food and shelter. Spokespeople can speak to findings from a recent Ipsos poll conducted for CanadaHelps with insights on Canadians turning to charities for support, including: Spokespeople can highlight a variety of easy ways Canadians can participate in GivingTuesday, including donating to a favourite charity or cause, volunteering, fundraising, setting up a monthly donation, purchasing Charity Gift Cards (as holiday season gifts and stocking stuffers), performing acts of kindness, and so much more. Impact of Canada Post Strike on Charities Like so many small businesses that rely on postal service to deliver packages, many charities rely on direct mail which represents a critical portion of their annual revenue. With the Canada Post strike, many charities are concerned that they will be forgotten among supporters who would normally mail in a cheque at the end of the year. Spokespeople can speak to the impact of the labour dispute on Canada's charitable sector, can share examples of charities in select cities that are affected, and offer alternatives to traditional mail for giving. Challenges Facing Arts and Culture Charities While the arts and culture sector provides significant personal and cultural benefits to Canadians, according to new Ipsos polling conducted for CanadaHelps , only 6% of the population says they prioritize arts and culture charities as important causes they support. Spokespeople can speak to the unique benefits of arts and culture organizations in uniting people, some of the challenges facing these charities, and highlight examples of the impact of specific arts charities in communities across Canada. Holiday Gifts that Make an Impact As Canadians search for the perfect gift to give this holiday season, spokespeople can discuss the variety of giving options for all budgets that can make a vital impact on charities and the communities that rely on them. Engaging Kids in Giving Spokespeople can speak to creative ways that parents can use GivingTuesday to engage children in giving while also learning about specific causes of interest and impact. Companies Leveraging GivingTuesday to Support Charities Companies across the country are embracing GivingTuesday as a way to make a positive impact. Spokespeople can highlight how businesses are supporting charities, how it benefits their organizations, and provide examples of how select companies are supporting this day of generosity. Financial Ways to Give Strategically Spokespeople can speak to strategic ways of giving and using charitable tax benefits to receive up to 49% of their contribution back as a tax credit. They can also discuss how monthly donations and donations of securities are strategic ways to give and how these methods grew 11% and 32% respectively on CanadaHelps in 2023 compared to the prior year. Top Causes and Giving Trends For 11 consecutive years, fewer Canadians have been engaging in charitable giving. Canada Revenue Agency tax filer data shows donation rates declined from 23.4 percent in 2010 to 17.7 percent in 2021 (among those Canadians claiming tax receipts). Spokespeople can speak to popular causes Canadians are supporting, ways Canadians are giving, and how we can reverse declines in the number of Canadians who give. Uniting Communities Through Generosity Canadians are increasingly disconnected and have shrinking social networks, which is correlated with lower rates of giving. Recent global data also highlighted how Canada is the second most polarized nation when it comes to giving, only behind Great Britain.* Spokespeople are available to speak to these trends and how generosity can unite communities this holiday season. The Impact and History of GivingTuesday GivingTuesday has global roots and has made a local impact. Launched in 2012 in the United States as a response to Black Friday and Cyber Monday and brought to Canada in 2013 by CanadaHelps, GivingTuesday is now celebrated in more than 90 countries. In Canada, an estimated six million Canadians have participated in GivingTuesday. Resources: *GivingTuesday Global, The Giving Bridge: A Lookback at 2023 Trends in Global Generosity CONTACT: Jodi Echakowitz Boulevard PR (on behalf of CanadaHelps) [email protected]Reps plan law on installation, use of CNG tanks